English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18240/20438 (89%)
造訪人次 : 5455412      線上人數 : 1435
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34800


    標題: Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma
    作者: Liang, Peir-In
    Lai, Hong-Yue
    Chan, Ti-Chun
    Li, Wei-Ming
    Hsing, Chung-Hsi
    Huang, Steven K. K.
    Hsieh, Kun-Lin
    Tseng, Wen-Hsin
    Chen, Tzu-Ju
    Li, Wan-Shan
    Chen, Huan-Da
    Kuo, Yu-Hsuan
    Li, Chien-Feng
    貢獻者: Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pathol
    Chi Mei Med Ctr, Dept Med Res
    Natl Hlth Res Inst, Natl Inst Canc Res
    Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Urol
    Kaohsiung Med Univ, Coll Med, Sch Med, Dept Urol
    Kaohsiung Med Univ, Ctr Liquid Biopsy & Cohort Res
    Pingtung Hosp, Dept Urol, Minist Hlth & Welf
    Chi Mei Med Ctr, Dept Anesthesiol
    , Tainan 710402, Taiwan;[Huang, Steven K. K.
    Chang Jung Christian Univ, Coll Hlth Sci, Dept Med Sci Ind
    Chi Mei Med Ctr, Dept Clin Pathol
    Chung Hwa Univ Med Technol, Dept Med Technol
    Chi Mei Med Ctr, Dept Pathol
    Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol
    Chia Nan Univ, Coll Pharm & Sci
    關鍵字: Dihydropyrimidinase-like 3 (DPYSL3)
    Upper urinary tracts urothelial carcinoma (UTUC)
    Urinary bladder urothelial carcinoma (UBUC)
    Cytoskeleton modification
    Mammalian target of rapamycin (mTOR)
    Ribosomal protein S6 (RPS6)
    Cellular Myelocytomatosis (C-Myc)
    Glucose transporter 1 (GLUT1)
    Metabolic process reprogramming
    日期: 2023
    上傳時間: 2024-12-25 11:03:42 (UTC+8)
    出版者: BMC
    摘要: BackgroundDihydropyrimidinase-like 3 (DPYSL3) is a cytosolic phosphoprotein expressed in the nervous system and is crucial for neurogenesis. A previous study showed that increased DPYSL3 expression promotes tumour aggressiveness in pancreatic ductal adenocarcinoma, gastric cancer, and colon cancer. However, the role of DPYSL3 in affecting the biological behaviour of urothelial carcinoma (UC) is not yet understood.MethodsA UC transcriptomic dataset from the Gene Expression Omnibus and the Urothelial Bladder Cancer (BLCA) dataset from The Cancer Genome Atlas were used for the in silico study. We collected 340 upper urinary tract urothelial carcinoma (UTUC) and 295 urinary bladder urothelial carcinoma (UBUC) samples for the immunohistochemical study. Fresh tumour tissue from 50 patients was used to examine the DPYSL3 mRNA level. In addition, urothelial cell lines with and without DPYSL3 knockdown were used for the functional study.ResultsThe in silico study revealed that DPYSL3 correlated with advanced tumour stage and metastasis development while functioning primarily in the nucleobase-containing compound metabolic process (GO:0006139). DPYSL3 mRNA expression is significantly upregulated in advanced UC. Furthermore, overexpression of the DPYSL3 protein is significantly associated with the aggressive behaviour of UTUC and UBUC. DPYSL3 expression independently predicts disease-specific survival (DSS) and metastatic-free survival (MFS) in patients with UC. In non-muscle-invasive UBUC, DPYSL3 expression predicts local recurrence-free survival. UC cell lines with DPYSL3 knockdown exhibited decreased proliferation, migration, invasion, and human umbilical vein endothelial cells (HUVECs) tube formation but increased apoptosis and G1 arrest. Gene ontology enrichment analysis revealed that the enriched processes related to DPYSL3 overexpression in UC were tissue morphogenesis, cell mesenchyme migration, smooth muscle regulation, metabolic processes, and RNA processing. In vivo study revealed DPYSL3 knockdown in UC tumours significantly suppressed the growth of tumours and decreased MYC and GLUT1 protein expression.ConclusionsDPYSL3 promotes the aggressiveness of UC cells by changing their biological behaviours and is likely associated with cytoskeletal and metabolic process modifications. Furthermore, DPYSL3 protein overexpression in UC was associated with aggressive clinicopathological characteristics and independently predicted poor clinical outcomes. Therefore, DPYSL3 can be used as a novel therapeutic target for UC.
    關聯: Bmc Cancer, v.23, n.1, Article 599
    顯示於類別:[行政單位] 456

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML0檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋